Substance / Medication

Arformoterol

Overview

Active Ingredient
arformoterol
RxNorm CUI
304962

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

18 trials linked to this intervention

18
Total Trials
2
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma.
Hinkle J, Hinson J, Kerwin E et al. · Pediatr Pulmonol · 2011
PMID: 21584948RCT
Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
Celli Bartolome R, Navaie Maryam, Xu Zhun et al. · Int J Chron Obstruct Pulmon Dis · 2019
PMID: 31190787ObservationalFull text (PMC)
Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Ganapathy Vaidyanathan, Stensland Michael D · Int J Chron Obstruct Pulmon Dis · 2017
PMID: 28694692ObservationalFull text (PMC)
Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.
Donohue James F, Ganapathy Vaidyanathan, Bollu Vamsi et al. · Clin Ther · 2017
PMID: 28011247Observational
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
Donohue James F, Hanania Nicola A, Make Barry et al. · Chest · 2014
PMID: 25451347ObservationalFull text (PMC)
Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu Vamsi, Ernst Frank R, Karafilidis John et al. · Int J Chron Obstruct Pulmon Dis · 2013
PMID: 24353413ObservationalFull text (PMC)
The safety and efficacy of arformoterol and formoterol in COPD.
Hanania Nicola A, Donohue James F, Nelson Harold et al. · COPD · 2010
PMID: 20214460Observational
Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin D P, Donohue J F, Mahler D A et al. · Respir Med · 2009
PMID: 19208459Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Arformoterol (substance)
SNOMED CT
423347007
UMLS CUI
C0969589
RxNorm CUI
304962

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
18
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.